GeneFerm Biotechnology Co (1796.TWO) Stock Price

GeneFerm Biotechnology Co Price

CLOSED
29.70TWD+0.00 (+0.00 %)
Market closed

Over the last 12 years GeneFerm Biotechnology Co grew revenue by 9.8% annually, reaching 677.10 M TWD. Earnings per share have grown at 28.3% per year over the last 10 years. For GeneFerm Biotechnology Co, the net margin of 4.3% is down versus 11.0% a few years ago. At today's price the dividend yield works out to roughly 6.73%. The dividend has grown at 41.4% per year over the past 2 years. The stock trades about 2% above its 52-week low.

GeneFerm Biotechnology Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of GeneFerm Biotechnology Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how GeneFerm Biotechnology Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing GeneFerm Biotechnology Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

GeneFerm Biotechnology Co Stock Price History
DateGeneFerm Biotechnology Co Price
8/24/202629.70 TWD
8/21/202629.70 TWD
8/20/202629.35 TWD
8/19/202630.75 TWD
8/18/202630.30 TWD
8/17/202629.55 TWD
8/14/202630.70 TWD
8/13/202631.40 TWD
8/12/202630.75 TWD
8/11/202630.75 TWD
8/10/202630.60 TWD
8/7/202630.75 TWD
8/6/202630.90 TWD
8/5/202630.70 TWD
8/4/202631.55 TWD
8/3/202630.50 TWD
7/31/202631.40 TWD
7/30/202631.05 TWD
7/29/202629.00 TWD
7/28/202630.35 TWD
7/27/202631.00 TWD
7/24/202631.00 TWD
7/23/202631.10 TWD
7/22/202631.85 TWD
7/21/202631.75 TWD
7/20/202630.70 TWD
7/17/202631.80 TWD
7/16/202632.35 TWD
7/15/202632.85 TWD
7/14/202632.50 TWD
7/13/202632.80 TWD
7/10/202634.40 TWD
7/9/202634.40 TWD
7/8/202638.20 TWD
7/7/202634.75 TWD
7/6/202631.60 TWD
7/3/202632.35 TWD
7/2/202632.10 TWD
7/1/202631.85 TWD
6/30/202631.85 TWD
6/29/202631.95 TWD
6/26/202632.25 TWD
6/25/202633.00 TWD
6/24/202633.00 TWD
6/23/202633.50 TWD
6/22/202634.20 TWD
6/18/202634.00 TWD
6/17/202633.75 TWD
6/16/202633.95 TWD
6/15/202633.95 TWD
6/12/202634.60 TWD
6/11/202634.35 TWD
6/10/202634.35 TWD
6/9/202635.10 TWD
6/8/202635.20 TWD
6/5/202636.40 TWD
6/4/202636.65 TWD
6/3/202636.60 TWD
6/2/202636.15 TWD
6/1/202635.50 TWD
5/29/202635.90 TWD
5/28/202635.90 TWD
5/27/202635.55 TWD
5/26/202636.50 TWD
5/25/202637.25 TWD
5/22/202638.50 TWD
5/21/202635.70 TWD
5/20/202636.00 TWD
5/19/202638.50 TWD
5/18/202635.00 TWD
5/15/202636.00 TWD
5/14/202635.60 TWD
5/13/202636.00 TWD
5/12/202637.00 TWD
5/11/202637.35 TWD
5/8/202637.55 TWD
5/7/202638.35 TWD
5/6/202637.60 TWD
5/5/202637.60 TWD
5/4/202637.80 TWD
4/30/202638.00 TWD
4/29/202638.10 TWD
4/28/202638.15 TWD
4/27/202638.20 TWD
4/24/202639.05 TWD
4/23/202639.90 TWD
4/22/202640.50 TWD
4/21/202640.60 TWD
4/20/202640.50 TWD
4/17/202639.55 TWD
4/16/202640.00 TWD
4/15/202640.00 TWD
4/14/202638.50 TWD
4/13/202639.40 TWD
4/10/202639.60 TWD
4/9/202641.10 TWD
4/8/202640.80 TWD
4/7/202641.10 TWD
4/2/202640.70 TWD
4/1/202637.00 TWD
3/31/202633.65 TWD
3/30/202635.40 TWD
3/27/202635.65 TWD
3/26/202636.55 TWD
3/25/202637.20 TWD
3/24/202637.60 TWD
3/23/202637.80 TWD
3/20/202638.35 TWD
3/19/202637.95 TWD
3/18/202638.05 TWD
3/17/202639.20 TWD
3/16/202639.20 TWD
3/13/202638.90 TWD
3/12/202638.80 TWD
3/11/202639.20 TWD
3/10/202639.15 TWD
3/9/202640.00 TWD
3/6/202641.60 TWD
3/5/202641.55 TWD
3/4/202641.20 TWD
3/3/202642.95 TWD
3/2/202643.15 TWD
2/26/202643.05 TWD
2/25/202643.10 TWD
2/24/202643.50 TWD
2/23/202643.75 TWD
2/11/202643.75 TWD
2/10/202643.60 TWD
2/9/202644.05 TWD
2/6/202644.30 TWD
2/5/202644.30 TWD
2/4/202644.50 TWD
2/3/202644.20 TWD
2/2/202644.20 TWD
1/30/202644.50 TWD
1/29/202645.30 TWD
1/28/202645.50 TWD
1/27/202645.60 TWD
1/26/202645.35 TWD
1/23/202645.00 TWD
1/22/202644.85 TWD
1/21/202644.80 TWD
1/20/202645.75 TWD
1/19/202645.85 TWD
1/16/202646.05 TWD
1/15/202646.00 TWD
1/14/202646.30 TWD
1/13/202646.20 TWD
1/12/202647.10 TWD
1/9/202646.60 TWD
1/8/202646.00 TWD
1/7/202646.00 TWD
1/6/202646.40 TWD
1/5/202646.20 TWD
1/2/202647.20 TWD
12/31/202548.25 TWD
12/30/202548.00 TWD
12/29/202548.10 TWD
12/26/202548.00 TWD
12/24/202549.40 TWD
12/23/202549.40 TWD
12/22/202549.00 TWD
12/19/202548.00 TWD
12/18/202549.00 TWD
12/17/202548.00 TWD
12/16/202549.90 TWD
12/15/202549.90 TWD
12/12/202548.00 TWD
12/11/202546.50 TWD
12/10/202547.00 TWD
12/9/202547.85 TWD
12/8/202546.80 TWD
12/5/202546.60 TWD
12/4/202546.45 TWD
12/3/202546.00 TWD
12/2/202545.70 TWD
12/1/202545.70 TWD
11/28/202545.90 TWD
11/27/202546.20 TWD
11/26/202546.10 TWD
11/25/202545.90 TWD
11/24/202545.70 TWD
11/21/202546.15 TWD
11/20/202546.85 TWD
11/19/202546.50 TWD
11/18/202546.60 TWD
11/17/202548.00 TWD
11/14/202548.15 TWD
11/13/202548.75 TWD
11/12/202548.50 TWD
11/11/202549.00 TWD
11/10/202550.60 TWD
11/7/202549.80 TWD
11/6/202550.30 TWD
11/5/202548.85 TWD
11/4/202549.00 TWD
11/3/202549.65 TWD
10/31/202548.40 TWD
10/30/202547.30 TWD
10/29/202547.70 TWD
10/28/202548.80 TWD
10/27/202549.65 TWD
10/23/202550.60 TWD
10/22/202550.90 TWD
10/21/202550.60 TWD
10/20/202550.30 TWD
10/17/202550.40 TWD
10/16/202551.10 TWD
10/15/202551.00 TWD
10/14/202550.90 TWD
10/13/202553.00 TWD
10/9/202552.00 TWD
10/8/202555.70 TWD
10/7/202553.20 TWD
10/3/202553.60 TWD
10/2/202554.20 TWD
10/1/202555.60 TWD
9/30/202557.40 TWD
9/26/202558.00 TWD
9/25/202559.30 TWD
9/24/202559.70 TWD
9/23/202559.30 TWD
9/22/202559.70 TWD
9/19/202558.90 TWD
9/18/202560.00 TWD
9/17/202561.00 TWD
9/16/202559.40 TWD
9/15/202559.90 TWD
9/12/202561.00 TWD
9/11/202560.50 TWD
9/10/202562.90 TWD
9/9/202564.80 TWD
9/8/202562.10 TWD
9/5/202559.10 TWD
9/4/202561.10 TWD
9/3/202564.80 TWD
9/2/202564.70 TWD
9/1/202564.50 TWD
8/29/202561.70 TWD
8/28/202561.10 TWD
8/27/202555.60 TWD
Access this data via the Eulerpool API
Get Free API Key

GeneFerm Biotechnology Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
357.45 M TWD
9.82 M TWD
10.32 M TWD
Jan 1, 2019
328.23 M TWD
-23.38 M TWD
-27.55 M TWD
Jan 1, 2020
368.30 M TWD
17.52 M TWD
4.53 M TWD
Jan 1, 2021
522.33 M TWD
79.15 M TWD
57.41 M TWD
Jan 1, 2022
633.96 M TWD
113.31 M TWD
93.45 M TWD
Jan 1, 2023
793.77 M TWD
157.18 M TWD
124.62 M TWD
Jan 1, 2024
521.16 M TWD
-35.49 M TWD
-22.53 M TWD
Jan 1, 2025
677.10 M TWD
46.04 M TWD
28.86 M TWD

GeneFerm Biotechnology Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 6:25 AM
 
REVENUEM TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM TWD
EBITM TWD
EBIT MARGIN%
NET INCOMEM TWD
NET INCOME GROWTH%
DIV.TWD
DIV. GROWTH%
SHARESM
2013201420152016201720182019202020212022202320242025
219.00222.00375.00452.00349.00357.00328.00368.00522.00633.00793.00521.00677.00
–1.3768.9220.53-22.792.29-8.1212.2041.8521.2625.28-34.3029.94
36.0727.4840.2750.0042.1232.7723.4832.8836.7835.0736.0718.4328.06
79.0061.00151.00226.00147.00117.0077.00121.00192.00222.00286.0096.00190.00
6.00-18.0054.00116.0036.009.00-23.0017.0079.00113.00157.00-35.0046.00
2.74-8.1114.4025.6610.322.52-7.014.6215.1317.8519.80-6.726.79
5.00-18.0054.0094.0028.0010.00-27.004.0057.0093.00124.00-22.0028.00
–-460.00-400.0074.07-70.21-64.29-370.00-114.811,325.0063.1633.33-117.74-227.27
–––––––––1.001.502.00–
––––––––––50.0033.33–
24.0524.0524.0525.3641.4641.4641.4627.8940.7941.4641.8741.4641.46
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales GeneFerm Biotechnology Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue GeneFerm Biotechnology Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare GeneFerm Biotechnology Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares GeneFerm Biotechnology Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against GeneFerm Biotechnology Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

GeneFerm Biotechnology Co stock margins

The GeneFerm Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GeneFerm Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GeneFerm Biotechnology Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
32.99 %
2.75 %
2.89 %
Jan 1, 2019
23.62 %
-7.12 %
-8.39 %
Jan 1, 2020
33.12 %
4.76 %
1.23 %
Jan 1, 2021
36.88 %
15.15 %
10.99 %
Jan 1, 2022
35.04 %
17.87 %
14.74 %
Jan 1, 2023
36.07 %
19.80 %
15.70 %
Jan 1, 2024
18.56 %
-6.81 %
-4.32 %
Jan 1, 2025
28.18 %
6.80 %
4.26 %

GeneFerm Biotechnology Co Stock Revenue, EBIT, Earnings per Share

The GeneFerm Biotechnology Co earnings per share therefore indicates how much revenue GeneFerm Biotechnology Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 TWD
0.00 TWD
0.00 TWD
Jan 1, 2019
0.00 TWD
0.00 TWD
0.00 TWD
Jan 1, 2020
13.20 TWD
0.63 TWD
0.16 TWD
Jan 1, 2021
12.81 TWD
1.94 TWD
1.41 TWD
Jan 1, 2022
15.29 TWD
2.73 TWD
2.25 TWD
Jan 1, 2023
18.96 TWD
3.75 TWD
2.98 TWD
Jan 1, 2024
12.57 TWD
-0.86 TWD
-0.54 TWD
Jan 1, 2025
0.00 TWD
0.00 TWD
0.00 TWD

GeneFerm Biotechnology Co business model & stock analysis

GeneFerm Biotechnology Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

GeneFerm Biotechnology Co historical P/E ratio, EBIT multiple, and P/S ratio

GeneFerm Biotechnology Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

GeneFerm Biotechnology Co shares outstanding

The number of shares of GeneFerm Biotechnology Co was 41.46 M in 2025. This indicates how many shares GeneFerm Biotechnology Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
25.36 M Stocks
Jan 1, 2019
25.36 M Stocks
Jan 1, 2020
27.89 M Stocks
Jan 1, 2021
40.79 M Stocks
Jan 1, 2022
41.46 M Stocks
Jan 1, 2023
41.87 M Stocks
Jan 1, 2024
41.46 M Stocks
Jan 1, 2025
41.46 M Stocks

GeneFerm Biotechnology Co Dividend History

3 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20242.00TWD↑ 33.3%1×
20231.50TWD↑ 50.0%1×
20221.00TWD—1×

GeneFerm Biotechnology Co dividend payout ratio

In 2025, GeneFerm Biotechnology Co had a payout ratio of 47.38%. The payout ratio indicates the percentage of the company's profits that GeneFerm Biotechnology Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
47.38 %
Jan 1, 2019
47.38 %
Jan 1, 2020
47.38 %
Jan 1, 2021
47.38 %
Jan 1, 2022
44.36 %
Jan 1, 2023
50.40 %
Jan 1, 2024
-368.08 %
Jan 1, 2025
47.38 %
Price targets and forecasts for GeneFerm Biotechnology Co are not yet available.

GeneFerm Biotechnology Co shareholder structure

% Name
28.94356%
Syngen Biotech Co., Ltd.
Syngen Biotech Co., Ltd.
5.17366%
Standard Foods Corp
Standard Foods Corp
3.79402%
Chang (Hsiao Li-a)
Chang (Hsiao Li-a)
2.99807%
Jimont Company Ltd.
Jimont Company Ltd.
2.63386%
Hsiao (Hsing Yih-a)
Hsiao (Hsing Yih-a)
2.04776%
Song Yien Enzyme Corporation
Song Yien Enzyme Corporation

GeneFerm Biotechnology Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
49.9%
Float Shares
-
Shares Outstanding
-

GeneFerm Biotechnology Co Executives and Management Board

11 members · 18 % women

Management

FH

Mr. Frank Hsiao

Deputy General Manager-Sales & Marketing Division

–
QS

Ms. Qimian Su

Head of Finance & Accounting, Corporate Governance Officer

–

Board of Directors

GC

Ms. Grance Chang

Chairman of the Board · since 2000

–
JJ

Mr. Jinn-Der Jin

General Manager, Director · since 2007

–
WC

Mr. Wei-Jen Chen

Director

–
ZF

Mr. Ziting Fan

Director

–
YJ

Mr. Yiren Ji

Director

–
YY

Mr. Yih Chun Yao

Director

–

Frequently asked questions about GeneFerm Biotechnology Co

Converted at the current exchange rate, the GeneFerm Biotechnology Co share trades at 0.80 EUR (29.70 TWD).

No history available for GeneFerm Biotechnology Co.

The revenue cannot currently be calculated for GeneFerm Biotechnology Co.

The profit cannot currently be calculated for GeneFerm Biotechnology Co.

The P/E ratio cannot be calculated for GeneFerm Biotechnology Co at the moment.

The P/S cannot be calculated for GeneFerm Biotechnology Co currently.

The Eulerpool Quality Score for GeneFerm Biotechnology Co is 2/10.

The ISIN of GeneFerm Biotechnology Co is TW0001796001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of GeneFerm Biotechnology Co is 1796.TWO. The ticker symbol is used to trade GeneFerm Biotechnology Co shares on the stock exchange.

Over the past 12 months, GeneFerm Biotechnology Co paid a dividend of 2.00 TWD . This corresponds to a dividend yield of about 6.73 %. For the coming 12 months, GeneFerm Biotechnology Co is expected to pay a dividend of 2.00 TWD.

The current dividend yield of GeneFerm Biotechnology Co is 6.73 %.

GeneFerm Biotechnology Co paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 2.00 TWD are expected. This corresponds to a dividend yield of 6.73 %.

GeneFerm Biotechnology Co is assigned to the 'Non-cyclical consumption' sector.

To receive the latest dividend of GeneFerm Biotechnology Co from amounting to 2 TWD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, GeneFerm Biotechnology Co distributed 1.5 TWD as dividends.

The dividends of GeneFerm Biotechnology Co are distributed in TWD.

All fundamentals and in-depth analysis of GeneFerm Biotechnology Co

Our stock analysis for GeneFerm Biotechnology Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GeneFerm Biotechnology Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Revenue→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Net Income→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co P/E→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co P/S→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co EBIT→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Dividend→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Directors Dealings→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Stocks→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Market capitalization→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Debt→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Liabilities→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Equity→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co AAQS→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Employees→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co ROE→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co ROA→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co ROCE→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co News→
GeneFerm Biotechnology Co Stock
GeneFerm Biotechnology Co Analyst Price Targets→

Non-cyclical consumption Stocks

General MillsGeffen Residence & RenewalGenic CoGdh Supertime Group CoGenix PharmaceuticalsGayatri SugarsGenky DrugStores CoGayatri BioOrganicsGenufood Energy EnzymesGarudafood Putra Putri Jaya Tbk PTGeorge WestonGaodi HoldingsAll Stocks A–Z →